Spots Global Cancer Trial Database for vascular endothelial growth factor (vegf)
Every month we try and update this database with for vascular endothelial growth factor (vegf) cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Sunitinib Malate (SUO11248) In Subjects W/ Metastatic And/Or Surgically Unresectable Hepatocellular Cancers (HCC) | NCT00495625 | Liver Cancer | Sunitinib Malat... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Phase I Trial of Vandetanib Combined With 131I-mIBG to Treat Patients With Advanced Phaeochromocytoma and Paraganglioma | NCT01941849 | Phaeochromocyto... Paraganglioma | Vandetanib 131I-mIBG | 18 Years - | University College, London | |
| Phase I Trial of Vandetanib Combined With 131I-mIBG to Treat Patients With Advanced Phaeochromocytoma and Paraganglioma | NCT01941849 | Phaeochromocyto... Paraganglioma | Vandetanib 131I-mIBG | 18 Years - | University College, London | |
| A Study of TRC105 in Combination With Paclitaxel/Carboplatin and Bevacizumab in Non-Squamous Cell Lung Cancer | NCT02429843 | Lung Cancer | TRC105 | 19 Years - | University of Alabama at Birmingham | |
| Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma | NCT00917384 | Gastric Cancer Adenocarcinoma | ramucirumab Placebo Best Supportive... | 18 Years - | Eli Lilly and Company | |
| Clinical Outcomes for Patients With Renal Cell Carcinoma Who Received First-Line Sunitinib | NCT04076787 | Metastatic Rena... | Sunitinib | 18 Years - | Pfizer | |
| Safety and Tolerability of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration | NCT00504959 | Subfoveal Choro... Secondary to Ag... | ranibizumab | 50 Years - | Novartis | |
| Sunitinib Malate (SUO11248) In Subjects W/ Metastatic And/Or Surgically Unresectable Hepatocellular Cancers (HCC) | NCT00495625 | Liver Cancer | Sunitinib Malat... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| A Study of TRC105 in Combination With Paclitaxel/Carboplatin and Bevacizumab in Non-Squamous Cell Lung Cancer | NCT02429843 | Lung Cancer | TRC105 | 19 Years - | University of Alabama at Birmingham | |
| Clinical Outcomes for Patients With Renal Cell Carcinoma Who Received First-Line Sunitinib | NCT04076787 | Metastatic Rena... | Sunitinib | 18 Years - | Pfizer | |
| Sunitinib Malate (SUO11248) In Subjects W/ Metastatic And/Or Surgically Unresectable Hepatocellular Cancers (HCC) | NCT00495625 | Liver Cancer | Sunitinib Malat... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| A Study of TRC105 in Combination With Paclitaxel/Carboplatin and Bevacizumab in Non-Squamous Cell Lung Cancer | NCT02429843 | Lung Cancer | TRC105 | 19 Years - | University of Alabama at Birmingham |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
